Aims
Introduction
Inflammatory dilated cardiomyopathy (iDCM) is an important cause of heart failure and sudden death in children and young patients. 1 Progressive cardiac dilation and fibrosis are hallmarks of iDCM in humans. iDCM refers to an end-stage heart failure phenotype that often results from virus-triggered myocarditis. 2 Both clinical observations and animal experiments suggest that infection-triggered autoimmunity plays an important role in iDCM. 3 Heart-specific autoimmune responses are a consequence of the lack of T cell tolerance to heart-specific alpha-myosin heavy chain (aMyHC) in mice and in humans. 4 Experimental autoimmune myocarditis (EAM) is a CD4 + T cellmediated mouse model of iDCM. In susceptible mouse strains, EAM is commonly induced after immunization with aMyHC peptide together with a strong adjuvant. 4 In BALB/c mice, the extent of cardiac infiltrates peaks 3 weeks after immunization. Inflammatory infiltrates largely resolve thereafter, but the process of pathological remodelling continues and many mice develop an end-stage heart failure phenotype, including ventricular dilation, myocardial fibrosis, and heart failure on follow-up. 5 At the peak of EAM, inflammatory cells, including granulocytes, monocytes, macrophages, T cells, B cells, and CD133
+ progenitors, infiltrate the myocardium. 4, 6 CD133 (prominin-1) and its human orthologue, AC133, are often expressed on primitive cell populations including haematopoietic stem cells. In EAM, bone marrow-derived CD133 + progenitors represent the major cellular source of collagenproducing fibroblasts involved in the progressive transforming growth factor-beta (TGF-b)-mediated cardiac remodelling, 6 which reflects the transition from acute inflammation into the typical end-stage heart failure phenotype. Macrophages represent another important heart-infiltrating cell subset in EAM 7 . In mice, macrophages commonly express the F4/80 antigen. Their role in disease pathogenesis, however, remains controversial. So far, the nitric oxide synthase 2 (NOS2)-expressing M1 macrophage subset had been considered to contribute to disease progression, 7, 8 On the other hand, nitric oxide also acts as a strong immunosuppressive molecule preventing EAM development via induction of T cell apoptosis. 6 Alternatively, activated M2 macrophages are considered to promote resolution of inflammation and reduce disease severity. 7 -9 Macrophage-colony-stimulating factor (M-CSF) is one of the key cytokines regulating immune responses and reparative processes in many inflammatory and cardiovascular disorders. 10, 11 M-CSF plays a pivotal role in differentiation and maturation of the macrophage myeloid lineage. 12 Mice lacking functional M-CSF show macrophage deficiency, reduced phagocytosis, and strongly impaired nitric oxide production. 13 In animal models of ischaemic heart failure and viral myocarditis, M-CSF treatment improves cardiac function, 14 -16 but the mechanism is still unclear. We hypothesize that altering the in vivo fate of inflammatory progenitors by selectively promoting macrophage lineage differentiation may protect from myofibroblast accumulation and cardiac fibrosis in EAM. In fact, M-CSF-induced conversion of heart-infiltrating 
Histopathology and immunocytochemistry
Hearts were formalin-fixed and paraffin embedded. Heart sections were stained with rat anti-mouse CD45 (BD Bioscience), rabbit anti-mouse CD3 (Neomarkers), rat anti-mouse F4/80 (BMA biomedicals) and rabbit anti-rat IgG (Abcam) antibodies, and with the Bond Polymer Refine Detection kit using the BOND-MAX system (both Leica). Masson's Trichrom staining was used to detect fibrosis. Immunopositive cells and fibrotic areas were quantified using analysis FIVE software (Olympus).
Echocardiography
Mice were lightly anaesthetized with 1 -1.5% isoflurane, maintaining the heart rate at 400 -500 b.p.m. Transthoracic echocardiography was performed using a 30 MHz probe and the Vevo 770 Ultrasound system (VisualSonics) as described 17 and in Supplementary Material online.
Cell cultures
Myocarditis-positive hearts were perfused, dissected, and digested with Liberase Blendzyme (Roche) for 45 min at 378C and tissue suspensions were passed sequentially through 70 and 40 mm cell strainers. Cardiomyocytes were separated by low speed centrifugation (50 g, 2 min). CD133 + cells were isolated by positive selection using anti-CD133-PE antibody (eBioscience) and magnetic anti-PE-microbeads (Miltenyi) or using FACS. Enriched CD133 + cells were plated onto gelatine-coated cell culture plates and cultured in the Iscove's Modified Dulbecco's Medium supplemented with 20% foetal bovine serum, 1:100 penicillin/ streptomycin, 100 mM non-essential amino acids, 100 mM sodium pyruvate, and 50 mM b-mercaptoethanol (all Invitrogen). Macrophage differentiation was induced with 10 ng/mL M-CSF, and fibroblast differentiation with 10 ng/mL TGF-b (both PeproTech).
Flow cytometry and cell sorting
Single cell suspensions were prepared from digested hearts and cultured cells. Cells were incubated 30 min on ice with the appropriate combination of fluorochrome-or biotin-conjugated antibodies. The following antibodies were used: anti-CD45-FITC, anti-CD45-PE, anti-NOS2-FITC (all BD Bioscience), anti-CD133-PE, anti-F4/80-PE (both eBioscience), biotin-conjugated anti-F4/80 (Cedarlane), anti-CD16/32 (Miltenyi), anti-CD206 (Biolegend), anti-CD301 (Serotec), and anti-CD133 (eBioscience). Streptavidin-APC (BD Bioscience) was used to detect biotin-conjugated antibodies. Cells were analysed with the FACSCanto analyser (BD Bioscience) and FlowJo software (Tree Star). In some experiments, cells were sorted with FACSAria III (BD Bioscience).
Quantitative RT-PCR
Total RNA was isolated using the RNeasy micro kit (Qiagen). cDNAs were amplified using the Power SYBR Green PCR Master Mix (Applied Biosystems) and oligonucleotides complementary to transcripts of the analysed genes using the 7500 Fast Real-Time PCR System (Applied Biosystems). The following oligonucleotides were used in this study:
Transcript levels of gapdh were used as an endogenous reference, and relative gene expression was analysed using the 2 2DDCt method.
Immunohistochemistry and phagocytosis assays
Cells were cultured on gelatine-coated cover slips and fixed with 4% paraformaldehyde or methanol:acetone (7:3). One per cent bovine serum albumin was used as blocking solution. The following antibodies were used: mouse IgG anti-aSMA (Sigma), rabbit IgG anti-fibronectin (Milipore), AlexaFluor488 anti-mouse IgG, and AlexaFluor546 anti-rabbit IgG 1:600 (both Invitrogen). 4 ′ ,6-diamidino-2-phenylindole was used to label nuclei. Alexa Fluor 488-conjugated Escherichia coli BioParticles (Invitrogen) were used according to manufacturer's recommendations. Immunofluorescence was analysed using the Olympus BX51 fluorescence microscope.
Statistics
Normally distributed data were analysed by the unpaired, two-tailed Student's t-test, and by one-way ANOVA followed by the Bonferroni post hoc test. Severity scores were analysed by the one-way Kruskal -Wallis analysis. For correlation analysis, Pearson's correlation coefficient was calculated. All analyses were computed using the GraphPad Prism 5 software. Differences were considered as statistically significant for P , 0.05.
Results

M-CSF converts heart-infiltrating CD133
1 progenitors into functional F4/80 In cytokine-free cultures, most expanded cells remained positive for CD133 and were mainly negative for macrophage marker F4/80 (Supplementary material online, Figure S1A and B). In the presence of M-CSF, however, CD133 expression was reduced (Supplementary material online, Figure S1A ) and cells up-regulated F4/80, CD11b, and CD16/32, suggesting macrophage lineage differentiation (Supplementary material online, Figure S1B -D). Cells cultured with M-CSF developed into fully active macrophages producing NOS2, secreting nitric oxide, and phagocyting E.coli bacteria (Supplementary material online, Figure S1E , F, and J). Of note, M-CSF treatment did not affect expression of markers characteristic for alternatively activated M2 macrophages (CD206, CD301, Supplementary material online, Figure S1G -H) or markers characteristic for granulocytes or dendritic cells, i.e. Gr-1 (Ly6C, Supplementary material online, Figure S1I ), MHC class II and CD11c (not shown).
To address the immunomodulating potential of CD133 + progenitors and CD133 + -derived M-CSF-differentiated macrophages, we co-cultured them with aMyHC-reactive Th17 cell lines in the presence of aMyHC-pulsed irradiated splenocytes as antigen presenting cells. On irradiated splenocytes, aMyHC-reactive CD4 + T cells proliferated rapidly. In the presence of CD133 + progenitors or M--CSF-differentiated macrophages, however, proliferation was completely abolished (Supplementary material online, Figure S2A ). Further, we induced EAM in BALB/c mice and additionally administrated iv 2 × 10 6 of either in vitro expanded CD133 + progenitors or CD133 + -derived mature macrophages at Day 7 after EAM induction and analysed myocarditis severity at Day 21. In animals treated with both CD133 + progenitors and M-CSF-differentiated macrophages, practically no myocarditis was observed compared with sham-treated mice (Supplementary material online, Figure S2B ). In contrast, the administration of M-CSF-differentiated macrophages expanded from Nos2 2/2 mice failed to protect from myocarditis (Supplementary material online, Figure S2C ). These latter findings confirm the protective and NOS2-dependent role of CD133 + -derived M-CSF-differentiated macrophages in EAM.
M-CSF treatment promotes accumulation of F4/80
1 macrophages in the post-inflammatory heart At Day 21, inflamed hearts contained a substantial pool of CD133 + progenitors, but fibrosis was not evident at this time point. As illustrated above, M-CSF effectively directs CD133
+ progenitors into functional macrophages and prevents their myofibroblast differentiation. We, therefore, analysed how systemic M-CSF treatment of aMyHC/CFA-immunized mice affects the pattern of heart-infiltrating cell subsets. Accordingly, aMyHC/CFA-immunized mice received M-CSF injections between Days 21 and 29 of EAM (Supplementary material online, Figure S3A ). Three days after the first M-CSF injection, we observed significantly increased number of F4/80 + and CD133
+ cells in the myocardium of M-CSF-treated mice (Day 24, Figure 2A and B). Immunopositive F4/80 + macrophages in the myocardium decreased over time and remained at low numbers at Day 40 ( Figure 2A ; Supplementary material online, Figure S4A and B). M-CSF treatments, however, did not affect the expression of CD16/32, CD206, and CD301 in inflammatory macrophages ( Figure 2E -G) . Instead, we observed significantly increased NOS2 on F4/80 + cells in the heart after M-CSF treatment of wild-type mice ( Figure 2D ).
M-CSF inhibits formation of myofibroblasts from inflammatory CD133 1 progenitors in EAM
Heart-infiltrating CD133 + progenitors represent the major cellular source of myofibroblasts in post-inflammatory EAM. 6 At Day 24 of Figure 2H) . We, therefore, analysed F4/80 expression on heart-infiltrating CD133 + progenitors in M-CSF-treated mice. We found that heart-infiltrating CD133 + / CD45 + cells of M-CSF-treated mice had higher expression of F4/80 at Day 24 (i.e. 3 days after the cytokine treatment, Figure 3C and D). Next, we sorted heart-infiltrating CD133 + /CD45 + cells from PBSand M-CSF-treated mice and found reduced mRNA levels of myofibroblast-specific genes in the M-CSF-treated group ( Figure 3E) . Furthermore, sorted heart-infiltrating CD133 + /CD45 + cells from both groups were plated and cultured in the presence of TGF-b for 10 days. CD133 + /CD45 + cells isolated from the myocardium of M-CSF-treated mice failed to differentiate into aSMA-and fibronectin-expressing myofibroblasts ( Figure 3F ). Bar ¼ 20 mm. ns P . 0.05, *P , 0.05, **P , 0.01, ***P , 0.001 (two-tailed Student's t-test).
NOS2 controls M-CSF
Altering in vivo fate of inflammatory progenitors from inflamed hearts of wild-type or Nos2 2/2 mice and cultivated in the presence of M-CSF. Nos2 2/2 CD133 + progenitors showed reduced F4/80 and CD14 expression and were functionally impaired as indicated by reduced E. coli phagocytosis ( Figure 4A and E). To determine whether macrophage differentiation was mediated by NOS activity, CD133 + progenitors isolated from inflamed hearts of BALB/c mice were cultured for 3 days in the presence of M-CSF with or without L-NAME, a non-specific NOS inhibitor. Cells cultured with L-NAME showed significantly reduced E. coli phagocytosis ( Figure 4F ) and reduced nitric oxide levels ( Figure 4G ).
M-CSF treatment prevents cardiac fibrosis and left ventricular dysfunction in EAM
M-CSF prevents TGF-b-mediated myofibroblast differentiation and promotes the formation of macrophages from inflammatory CD133 + progenitors. Given that CD133 + progenitors represent the major source for myofibroblasts in EAM, we addressed whether M-CSF treatment reduces fibrogenesis in the post-inflammatory heart. Accordingly, we treated aMyHC/CFA-immunized mice with M-CSF between Days 21 -29 or 40-48 of EAM, and analysed the hearts at Days 40 and 60, respectively (Supplementary material online, Figure S3A ). As illustrated in the Figure 5 , M-CSF treatment completely prevented accumulation of fibroblasts in the postinflammatory heart (Figure 5A -C; Supplementary material online, Figure S4B ). Of note, M-CSF treatment failed to attenuate fibrosis when delivered between Days 40 and 48 ( Figure 5A ). These findings suggest that M-CSF treatment prevented the fibrotic process, but did not revert already established cardiac fibrosis.
Relapses of inflammatory cells are quite common in autoimmune diseases. In BALB/c mice, we observed spontaneous inflammatory relapses 40 days after the first immunization ( Figure 5D and E).
During relapses, CD45
+ inflammatory cells were mainly detected in the pericardium and largely represented CD3 + T lymphocytes ( Figure 5D and E, Supplementary material online, Figure S3C ). Interestingly, M-CSF treatment between Days 21 and 29 inhibited relapses in aMyHC/CFA-immunized mice as reflected by reduced numbers of CD45 + and CD3 + T cells in the myocardium at Day 40 (Figure 5D and E; Supplementary material online, Figure S3C ). Altering in vivo fate of inflammatory progenitors Cardiac fibrosis parallels both, diastolic dysfunction, and reduced cardiac contractility. Not all immunized mice develop severe myocarditis. Consequently, the extent of post-inflammatory fibrosis varies in the EAM model. In our series, 11 out of 20 aMyHC/CFA-immunized BALB/c mice showed substantial fibrosis (.2% of total heart area) on Day 40. At this time point, echocardiography revealed reduced ejection fraction and fractional shortening in mice with significant fibrosis ( Figure 5F ). In addition, the extent of fibrosis correlated with increased mass, systolic and diastolic volume, and isovolumetric contraction time of the left ventricle (Supplementary material online, Figure   S5A ). Echocardiography of aMyHC/CFA-immunized and M-CSFtreated mice showed unaffected cardiac function at Day 40 ( Figure 5F , Supplementary material online, Figure S5E) .
Next, we immunized Nos2 
Discussion
We previously reported that in the EAM model post-inflammatory pathogenic myofibroblasts mainly originate from heart-infiltrating CD133 + progenitor cells. 6 In line with our previous findings, herein we demonstrate that M-CSF controls the formation of antiinflammatory macrophages from inflammatory CD133 + progenitors and prevents TGF-b-mediated differentiation into pathogenic myofibroblasts. Thus, our data suggest that in myocarditis, a significant pool of cells infiltrating the myocardium at the peak of disease represent non-committed progenitors. From a clinical perspective, it is important that the differentiation fate of multipotent, non-committed precursor cells infiltrating the myocardium, can be modulated via specific cytokine signalling in a controlled fashion. M-CSF is a key cytokine guiding macrophage differentiation in vitro 8 and in vivo. 18 In EAM, M-CSF treatment up-regulated F4/80 expression on CD133 + inflammatory progenitors promoting macrophage differentiation. In untreated mice, however, heartinfiltrating CD133 + progenitors spontaneously differentiate into pathogenic myofibroblasts. To our knowledge, this is the first report describing the change of in vivo fate of inflammatory progenitors naturally present in the inflamed organ. So far, it has been Altering in vivo fate of inflammatory progenitors described that M-CSF treatment improved cardiac function in a viral model of myocarditis, 16 after myocardial infarction 14, 15, 19 and in the ischaemia-reperfusion model. 20 Similar to our findings, M-CSF treatment promoted monocyte/macrophage accumulation in the heart after myocardial infarction 14, 15 or virus inoculation 16 .
Myocardial fibrosis plays a dual role in remodelling after cardiac injury. On one hand, it is a pre-requisite for wound healing, as in the case of ischaemic injuries, for example. On the other hand, it contributes to ventricular stiffening and typical pathological remodelling in heart failure. Our previous and current data clearly show that excessive cardiac fibrosis parallels impaired cardiac function in EAM. 17 Thus, preserved left ventricular function in M-CSF-treated mice results primarily from reduced myofibroblast differentiation, rather than protective macrophage activity. We propose that the conversion of inflammatory progenitors into functional macrophages, instead of myofibroblasts, represents a key mechanism explaining reduced fibrogenesis upon M-CSF treatment. However, we cannot rule out that M-CSF also activates other pathways inhibiting myocardial fibrogenesis. For example, M-CSF may protect cardiomyocytes from H 2 O 2 -induced death. 20 Moreover, M-CSF could affect extracellular matrix composition and levels of matrix metalloproteinases and cytokines/ chemokines, which drastically alter the myocardial microenvironment. Nevertheless, we can exclude direct M-CSF-mediated effects on cardiac fibroblasts, because upon M-CSF treatment during the late post-inflammatory phase of the EAM (Days 40 -48), the fibrosis was not reverted. It has been proposed that differential macrophage activation defines protective and pathogenic functions. Accordingly, adoptive transfer of M1 macrophages promoted histological disease scores, whereas injection of M2 macrophages was largely protective in Coxackievirusinduced myocarditis. 9 Also most heart-infiltrating macrophages were classified as M2 macrophages expressing mannose receptor and Gr-1 in aMyHC/CFA-and Coxackievirus-induced myocarditis. 7, 21 However, macrophages expressing M1 marker NOS2 have been identified in myocarditis as well. 22 We critically analysed macrophages in the myocardium after the peak of disease, during the post-inflammatory phase of EAM, and detected both, M1-and M2-specific markers. We were, however, unable to clearly delineate two distinct activation states. We assume that during EAM, heart-infiltrating macrophages were activated classically (M1) and alternatively (M2) at the same time. In fact, it is well known that T cells and other heart-infiltrating cells massively produce both M1-activating IFN-g as well as M2-activating IL-4 and IL-13. 7 Importantly, M-CSF treatment did not affect the expression of M1 and M2 markers except of NOS2. M-CSF-induced macrophage accumulation in the post-inflammatory heart was not pathogenic in our model, because resolution of inflammation, defined by the extent of inflammatory cells was clearly M-CSF independent. Moreover, M-CSF-induced macrophages showed strong immunosuppressive activity in vitro and in vivo. We believe that the accumulation of the immunosuppressive macrophages in M-CSF-treated mice protected from spontaneous T cell relapse. Nevertheless, we cannot, entirely rule out that M-CSF also mediates protective effects by acting on other target cells. We previously found that M-CSF-induced CD11b + monocytes prevented EAM development and suppressed CD4 + T cell proliferation in a nitric oxide-dependent manner. 23 M-CSF treatment promoted inflammatory macrophages expressing NOS2 in EAM, We, therefore, hypothesized that macrophage-produced nitric oxide might control both; T cell-mediated early inflammation as well as 27 At this stage, we cannot, however, exclude that in Nos2 2/2 mice, heart-infiltrating CD133 + progenitors are committed towards the fibroblast phenotype due to an alerted cytokine expression profile in the myocardium. Based on our findings, we can assume that M-CSF stimulates nitric oxide production that, in turn, promotes macrophage differentiation of inflammatory progenitors. In summary, our data demonstrate that a single haematopoietic cytokine, such as M-CSF can modulate the in vivo fate of inflammatory CD133
+ progenitors in a way to promote their differentiation into macrophages instead of myofibroblasts in the post-inflammatory phase of the EAM. Furthermore, our data suggest that mature inflammatory macrophages, in contrast to progenitor-derived fibroblasts, do not promote heart failure after acute myocarditis. These findings are in line with the clinical observation that fulminant myocarditis implies an excellent long-term prognosis, whereas subacute myocarditis usually progresses to end-stage heart failure. 28 
Supplementary material
Supplementary material is available at Cardiovascular Research online.
